Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Assignment history

Inventors

Joseph D. Panarese (Enanta Pharmaceuticals Inc.)
Dexter Davis (Enanta Pharmaceuticals Inc.)
Nathaniel Thomas Kenton (Enanta Pharmaceuticals Inc.)
Samuel Bartlett (Enanta Pharmaceuticals Inc.)
Sean M. Rafferty (Enanta Pharmaceuticals Inc.)
Yat Sun Or (Enanta Pharmaceuticals Inc.)

Original assignee

Enanta Pharmaceuticals Inc. is the original assignee named on the issued patent. Enanta Pharmaceuticals is a biotechnology company focused on the discovery and development of small molecule drugs, primarily for viral infections. They ship products embodying claims, such as glecaprevir for Hepatitis C. Enanta Pharmaceuticals Inc. is currently operating.

Assignment timeline

There are no assignment records for US11358953 on the USPTO Assignment Center search page.

The "Assigned to ENANTA PHARMACEUTICALS, INC." legal event on 2022-06-21, as noted in Google Patents, is a re-assignment of the original assignors' interest to the existing assignee and does not represent a change in ownership from a separate entity.

Timeline diagram

timeline
    title Ownership of US 11358953
    2021 : Filed by Enanta Pharmaceuticals Inc
    2022 : Issued to Enanta Pharmaceuticals Inc

NPE / troll-pattern signals

Shell-entity transfer — not present
Known asserter in the chain — not present
Repeat correspondent across the chain — not present
Cascading transfers — not present
Pre-litigation transfer — not present
Bankruptcy fire-sale — not present
Privateering — not present
Defensive aggregator (anti-NPE) — not present

Verdict

Insufficient data. There are no recorded assignments for US Patent 11358953 on the USPTO Assignment Center. The patent appears to remain with the original assignee, Enanta Pharmaceuticals Inc., which is an operating company. While there is litigation, the absence of assignment records means there is no evidence to suggest NPE involvement based on ownership transfers.

Verification: USPTO Assignment Center